Clinical trial Recruiting at 1 site Interventional Ages 18 to 40 Women only

Depth of Argon Beam Coagulation in Ovarian Endometriomas

Official title: Histological Assessment of Tissue Penetration Depth of Argon Beam Coagulation in Ovarian Endometriomas: A Prospective Pilot Study

Run by Insel Gruppe AG, University Hospital Bern · NCT07711743 · Data updated 2026-11-12

This study tests how deeply Argon Beam Coagulation affects ovarian tissue during laparoscopic surgery for ovarian endometriomas in women aged 18-40.

Quick facts

Study typeInterventional
Ages18 Years to 40 Years
SexWomen only
Enrollment50 (estimated)
SponsorInsel Gruppe AG, University Hospital Bern
Academic / other
Locations1 site (Bern, Canton of Bern)
StatusRecruiting
StartedJuly 9, 2026
Main results expectedJuly 7, 2027
Study endsAugust 7, 2027
Registry record updatedJuly 17, 2026
Trial IDNCT07711743 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18-40 with ovarian endometrioma ≥3 cm undergoing planned laparoscopic cystectomy.

Probably not a fit

Patients whose tissue is not severely affected by ABC or whose surgical path does not rely on ABC may have no additional benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center study measures the histological depth of tissue penetration by Argon Beam Coagulation used during laparoscopic cystectomy for ovarian endometriomas. During the planned operation, ABC is applied to the ovarian surface and the treated tissue is collected and examined under a microscope to quantify penetration depth and consistency. The goal is to generate data on the safety and tissue-preserving potential of ABC in endometriosis-related ovarian surgery. The study is conducted at University Hospital Bern and focuses on women with endometriomas ≥3 cm who require surgical treatment. Primary objective is to quantify penetration depth; secondary aims include consistency and implications for ovarian preservation.

Why it matters

Potential benefit: If successful, the data could support safer, more tissue-sparing surgical use of ABC in ovarian endometriosis, potentially preserving ovarian reserve.

How similar studies have gone: Previous use of ABC in endometriosis lacks robust histological depth data; this study provides novel, targeted tissue-depth findings.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female patients aged 18-40 years.
* Indication for surgical treatment of ovarian endometrioma based on clinical symptoms and/or imaging findings.
* Diagnosis of ovarian endometrioma ≥3 cm confirmed by preoperative imaging (ultrasound and/or MRI).
* Planned laparoscopic cystectomy.
* Written informed consent.

Exclusion Criteria:

* Expected lack of compliance or inability to understand the study procedures.
* Previous surgical procedures on the affected ovary.
* Recurrent ovarian endometrioma.
* Pregnancy or breastfeeding.
* Participation in another interventional clinical study that may influence study outcomes, such as anti-Müllerian hormone (AMH) levels or pregnancy.

Where it's running

  • University Hospital of Obstetrics and Gynecology, Inselspital Bern
    Bern, Canton of Bern, Switzerland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.